細胞解離胰蛋白酶-EDTA溶液市場 - 全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

全球用於細胞分離的胰蛋白酶-EDTA溶液市場預計將從2025年的20.2億美元成長到2031年的29.2億美元，複合年成長率達到6.33%。

胰蛋白酶-EDTA 是一種基礎酶試劑，用於細胞培養流程中，透過切割肽鍵和螯合整合素來支持陽離子，將貼壁細胞從基材分離。這個市場成長的主要驅動力是生物製藥生產的規模化，特別是單株抗體和疫苗的生產，以及再生醫學的快速發展，後者需要持續的細胞收穫。為了支持如此活躍的產業活動，根據國際細胞與基因治療學會 (ISCT) 統計，截至 2024 年，全球共有 3063 種細胞和基因療法處於開發平臺，因此需要大量可靠的細胞分離試劑來實現高效的上游工程加工。

儘管市場成長迅速，但仍面臨許多挑戰，包括胰蛋白酶對高度敏感的原代細胞株的潛在細胞毒性，以及對動物性成分的嚴格監管。這些擔憂促使企業越來越傾向於選擇重組或非酵素製劑，對傳統上佔據主導地位的豬源性胰蛋白酶-EDTA製劑構成挑戰。因此，製造商被迫不斷創新，以滿足現代治療藥物生產所需的嚴格安全標準。

市場促進因素

全球胰蛋白酶-EDTA市場的主要驅動力是生物製藥和生物製藥生產的快速擴張。隨著製藥公司積極拓展研發管線以應對複雜的疾病，生物製品生產和藥物篩檢所需的細胞培養工作量呈現爆炸性成長。上游工程的強化需要穩定的酵素試劑供應，以確保高效的細胞分離和傳代。根據國際藥品製造商協會聯合會（IFPMA）於2024年12月發布的《2024年事實與數據》報告，全球藥物開發平臺中處於不同研發階段的藥物超過12,700種，如此龐大的工作量導致中先導工廠和研究機構對分離液的需求持續成長。

同時，幹細胞療法和再生醫學的蓬勃發展正在為市場創造一個獨特的、高成長的領域。這些先進治療方法高度依賴間質幹細胞等黏附依賴性細胞，而這些細胞需要經過精確的酵素處理才能在收穫時保持活性。該領域強勁的資金實力正在加速臨床應用。根據再生醫學聯盟於2025年1月發布的《產業趨勢簡報》，2024年細胞和基因治療領域的投資成長了30%。這筆資金流入正在支持從研究到臨床試驗的過渡，並得益於有利的法規環境，包括美國食品藥物管理局（FDA）藥物評估與研究中心在2024年核准的50種新藥。

市場挑戰

由於擔心傳染性病原體和病毒污染，對動物性成分（尤其是豬胰蛋白酶）的嚴格監管成為市場准入的主要障礙。監管機構正在執行嚴格的安全通訊協定，以防止外來物質進入生物製藥生產過程，並要求進行廣泛的病毒去除測試和記錄。這種監管顯著增加了合規負擔，提高了製造商的營運複雜性和成本。因此，這些嚴格的要求阻礙了傳統配方的市場准入和擴充性生產，延緩了供應鏈，並影響了這些關鍵試劑的穩定供應。

這種強化品管的環境直接影響市場的穩定性和成長。根據美國藥典（USP）2024年藥品短缺年度報告，上年度藥品供應鏈中的產品停產率上升了40%，這一趨勢主要受生產複雜性和品質監控挑戰的影響。這些數據凸顯了監管壓力和相關的營運複雜性如何阻礙生產的連續性。在胰蛋白酶-EDTA市場，儘管細胞治療領域的需求不斷成長，但這些障礙限制了整體市場成長，並阻礙了動物性解決方案的順利推廣。

市場趨勢

在產業對高通量效率和可重複性需求的驅動下，胰蛋白酶處理通訊協定與自動化液體處理系統的整合正在顯著改變市場模式。實驗室正從手動分離轉向機器人平台，以最大限度地減少人為誤差並標準化細胞傳代，這需要黏度一致的酶製劑和專用包裝，以確保與機器人介面的兼容性。這種向自動化工作流程的轉變凸顯了對能夠在複雜儀器生態系統中無縫運作的可靠分離試劑的需求。根據Benchling於2024年11月發布的《2024年生物製藥技術趨勢報告》，83%的領先生物製藥公司已經實現了至少部分實驗室流程的自動化，這凸顯了關鍵的營運轉變，而這種轉變需要相容的酵素解決方案。

同時，類器官解離和3D細胞培養的應用領域正明顯超越傳統的單層培養技術。隨著研究人員在藥物篩檢中優先考慮生理相關模型，對能夠有效穿透球狀體和類器官內部緻密細胞外基質且不損害細胞活性的解離劑的需求日益成長。這項技術需求推動了市場對專門用於精細解離3D組織結構的最佳化酵素溶液的需求。例如，西奈健康研究所於2024年3月發布新聞稿宣布，已獲得1000萬美元投資，用於建立一個最先進的組織工程平台，專門用於開發複雜的人類類器官，以支持疾病研究和藥物發現。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：胰蛋白酶-EDTA細胞解離溶液的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（0.25%溶液，0.05%溶液）
  • 依應用領域（胰島素生產、疫苗生產、細胞培養等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美細胞解離用胰蛋白酶-EDTA溶液市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲細胞解離用胰蛋白酶-EDTA溶液市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區胰蛋白酶-EDTA細胞解離溶液的市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲細胞解離用胰蛋白酶-EDTA溶液的市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲細胞解離用胰蛋白酶-EDTA溶液的市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球胰蛋白酶-EDTA溶液細胞解離市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc
• Lonza Group Ltd
• Merck KGa
• Sartorius AG
• Biosera Europe
• Irvine Scientific
• Chargen Life Sciences LLP
• ScienCell Research Laboratories, Inc.
• STEMCELL Technologies Canada Inc.
• PromoCell GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Trypsin-EDTA Solution for Cell Dissociation Market is projected to expand from USD 2.02 Billion in 2025 to USD 2.92 Billion by 2031, achieving a CAGR of 6.33%. As a fundamental enzymatic reagent, Trypsin-EDTA is utilized in cell culture workflows to detach adherent cells from substrates by cleaving peptide bonds and chelating integrin-supporting cations. This market growth is primarily driven by the increasing scale of biopharmaceutical manufacturing, especially for monoclonal antibodies and vaccines, as well as the rapid advancement of regenerative medicine which requires consistent cell harvesting. Supporting this high level of industrial activity, data from the International Society for Cell & Gene Therapy indicates that in 2024, there were 3,063 cell and gene therapies in the global development pipeline, a landscape that necessitates substantial volumes of reliable cell dissociation agents for efficient upstream processing.

Despite this growth, the market faces significant hurdles regarding the potential cytotoxicity of trypsin towards sensitive primary cell lines and the strict regulatory scrutiny surrounding animal-derived components. These concerns are fostering a strategic preference for recombinant or non-enzymatic alternatives, posing a challenge to the traditional dominance of porcine-sourced Trypsin-EDTA formulations. Consequently, manufacturers are compelled to innovate continuously to uphold the rigorous safety standards required for modern therapeutic production.

Market Driver

The primary catalyst propelling the global trypsin-EDTA market is the rapid expansion of biopharmaceutical and biologics manufacturing. As pharmaceutical companies aggressively scale their pipelines to address complex pathologies, the volume of cell culture operations required for biological production and drug screening has surged. This intensification of upstream processing demands consistent supplies of enzymatic reagents to ensure efficient cell detachment and passage. According to the 'Facts & Figures 2024' report by the International Federation of Pharmaceutical Manufacturers & Associations in December 2024, the global pharmaceutical pipeline contained over 12,700 medicines in various stages of development, a massive workload that translates into sustained consumption of dissociation solutions across pilot plants and research laboratories.

Concurrently, the surge in stem cell therapy and regenerative medicine development is creating a specialized, high-growth avenue for the market. These advanced modalities rely heavily on anchorage-dependent cells, such as mesenchymal stem cells, which demand precise enzymatic treatment to maintain viability during harvesting. The sector's robust financial health is accelerating clinical translation; according to the Alliance for Regenerative Medicine's 'State of the Industry Briefing' in January 2025, investment in the cell and gene therapy sector increased by 30% in 2024. This influx of capital supports the transition from bench to bedside, further bolstered by a favorable regulatory environment where the FDA's Center for Drug Evaluation and Research approved 50 novel drugs in 2024.

Market Challenge

The market is significantly impeded by strict regulatory scrutiny regarding animal-derived components, specifically porcine-sourced trypsin, due to concerns over transmissible agents and viral contamination. Regulatory bodies enforce rigorous safety protocols to prevent the introduction of adventitious agents into biopharmaceutical workflows, necessitating extensive viral clearance testing and documentation. This oversight creates a substantial compliance burden, elevating operational complexity and costs for manufacturers. Consequently, these stringent requirements act as a barrier to entry and scalability for traditional formulations, slowing the supply chain and causing friction in the reliable distribution of these essential reagents.

This environment of heightened quality control directly impacts market stability and growth. According to the U.S. Pharmacopeia's 2024 Annual Drug Shortages Report, product discontinuations in the pharmaceutical supply chain rose by 40% during the preceding year, a trend heavily influenced by manufacturing complexities and quality oversight challenges. This statistic underscores how regulatory pressures and the resulting operational intricacies can disrupt production continuity. For the Trypsin-EDTA market, such hurdles limit the seamless expansion of animal-derived solutions, restricting overall market growth despite increasing demand from the cell therapy sector.

Market Trends

The integration of trypsinization protocols into automated liquid handling systems is significantly reshaping the market, driven by the industry's need for high-throughput efficiency and reproducibility. Laboratories are increasingly replacing manual dissociation with robotic platforms to minimize human error and standardize cell passage, necessitating enzyme formulations with consistent viscosity and specialized packaging for robotic interface compatibility. This shift toward automated workflows is substantiating the demand for reliable dissociation reagents that function seamlessly within complex instrument ecosystems. According to the '2024 State of Tech in Biopharma Report' by Benchling in November 2024, 83% of large biopharmaceutical companies have now automated at least some of their laboratory processes, highlighting the critical operational transition that requires compatible enzymatic solutions.

Simultaneously, there is a distinct expansion of application specifics for organoid dissociation and 3D cell culture, moving beyond traditional monolayer techniques. As researchers prioritize physiologically relevant models for drug screening, the demand is rising for dissociation agents capable of effectively penetrating dense extracellular matrices in spheroids and organoids without compromising cell viability. This technical requirement is pushing the market toward optimized enzymatic solutions tailored specifically for the delicate disaggregation of three-dimensional tissue structures. Highlighting this focus on advanced models, the Sinai Health institute announced in a March 2024 press release that it secured a $10 million investment to establish a state-of-the-art tissue engineering platform dedicated to developing complex human organoids for disease research and drug discovery.

Key Market Players

• Thermo Fisher Scientific Inc
• Lonza Group Ltd
• Merck KGa
• Sartorius AG
• Biosera Europe
• Irvine Scientific
• Chargen Life Sciences LLP
• ScienCell Research Laboratories, Inc.
• STEMCELL Technologies Canada Inc.
• PromoCell GmbH

Report Scope

In this report, the Global Trypsin-EDTA Solution for Cell Dissociation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Trypsin-EDTA Solution for Cell Dissociation Market, By Type

• 0.25% Solution
• 0.05% Solution

Trypsin-EDTA Solution for Cell Dissociation Market, By Application

• Insulin Manufacturing
• Vaccines Manufacturing
• Cell Culture
• Other

Trypsin-EDTA Solution for Cell Dissociation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Trypsin-EDTA Solution for Cell Dissociation Market.

Available Customizations:

Global Trypsin-EDTA Solution for Cell Dissociation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (0.25% Solution, 0.05% Solution)
  • 5.2.2. By Application (Insulin Manufacturing, Vaccines Manufacturing, Cell Culture, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Trypsin-EDTA Solution for Cell Dissociation Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lonza Group Ltd
• 15.3. Merck KGa
• 15.4. Sartorius AG
• 15.5. Biosera Europe
• 15.6. Irvine Scientific
• 15.7. Chargen Life Sciences LLP
• 15.8. ScienCell Research Laboratories, Inc.
• 15.9. STEMCELL Technologies Canada Inc.
• 15.10. PromoCell GmbH

16. Strategic Recommendations

17. About Us & Disclaimer